Gopalasingam et al., 2023 - Google Patents
Stimulation of the hydroxycarboxylic acid receptor 2 with the ketone body 3‐hydroxybutyrate and niacin in patients with chronic heart failure: hemodynamic and …Gopalasingam et al., 2023
View PDF- Document ID
- 6144593565513744483
- Author
- Gopalasingam N
- Christensen K
- Berg Hansen K
- Nielsen R
- Johannsen M
- Gormsen L
- Boedtkjer E
- Nørregaard R
- Møller N
- Wiggers H
- Publication year
- Publication venue
- Journal of the American Heart Association
External Links
Snippet
Background The ketone body 3‐hydroxybutyrate (3‐OHB) increases cardiac output (CO) in patients with heart failure through unknown mechanisms. 3‐OHB activates the hydroxycarboxylic acid receptor 2 (HCA2), which increases prostaglandins and suppresses …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| von Haehling et al. | Muscle wasting as an independent predictor of survival in patients with chronic heart failure | |
| Parsanathan et al. | Novel invasive and noninvasive cardiac-specific biomarkers in obesity and cardiovascular diseases | |
| Gormsen et al. | Ketone body infusion with 3‐hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study | |
| Jeong et al. | Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulating endothelial progenitor cells in diabetic patients with non–ST-segment elevation acute coronary syndrome requiring coronary stenting: a prospective, randomized, crossover trial | |
| Gopalasingam et al. | Stimulation of the hydroxycarboxylic acid receptor 2 with the ketone body 3‐hydroxybutyrate and niacin in patients with chronic heart failure: hemodynamic and metabolic effects | |
| Seki et al. | Acute and chronic increases of circulating FSTL1 normalize energy substrate metabolism in pacing-induced heart failure | |
| Mori et al. | ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4 | |
| Ito et al. | Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes | |
| Tomiyama et al. | The contribution of inflammation to the development of hypertension mediated by increased arterial stiffness | |
| Eikelboom et al. | Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events | |
| Polak et al. | Lipolytic effects of B-type natriuretic peptide1–32 in adipose tissue of heart failure patients compared with healthy controls | |
| Hundertmark et al. | Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial | |
| Thürmann et al. | Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension | |
| De Luca et al. | Evidence-based use of levosimendan in different clinical settings | |
| Willis et al. | Impaired oxidative metabolism and calcium mishandling underlie cardiac dysfunction in a rat model of post-acute isoproterenol-induced cardiomyopathy | |
| Kelm et al. | Evidence for a multifactorial process involved in the impaired flow response to nitric oxide in hypertensive patients with endothelial dysfunction | |
| Kamenický et al. | Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study | |
| Arora et al. | Weight loss, saline loading, and the natriuretic peptide system | |
| Brash et al. | Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension | |
| Rennison et al. | High-fat diet postinfarction enhances mitochondrial function and does not exacerbate left ventricular dysfunction | |
| Premilovac et al. | Muscle insulin resistance resulting from impaired microvascular insulin sensitivity in Sprague Dawley rats | |
| Xing et al. | Relationship of obesity to adverse events among patients with mean 10‐year history of type 2 diabetes mellitus: Results of the ACCORD Study | |
| Sasaki et al. | Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension | |
| Zhang et al. | Association of trimethylamine N-Oxide with cardiovascular and all-cause mortality in hemodialysis patients | |
| Straznicky et al. | A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome |